RTTNews | Aug 12, 2021 07:26AM EDT

07:25 Thursday, August 12, 2021 (RTTNews.com) - Global pharmaceutical company Cipla Limited has received final FDA approval for its Abbreviated New Drug Application for Difluprednate Ophthalmic Emulsion 0.05%. It is AB-rated generic therapeutic equivalent version of Novartis Pharmaceuticals Corporation's Durezol. The company said the product will be available for shipping soon.

Cipla's Difluprednate Ophthalmic Emulsion 0.05% is used for: treatment of inflammation and pain associated with ocular surgery; and treatment of endogenous anterior uveitis.

Cipla is focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets.

Read the original article on RTTNews ( https://www.rttnews.com/3218420/cipla-gets-fda-nod-for-generic-equivalent-of-novartis-durezol-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved